Technologies
Technologies
At IBSA, innovating is our daily challenge, the focal point of all our operations, and whose origin lies in a brilliant insight: to transform existing therapeutic solutions with known properties into simpler, more evolved instruments of care.
We are committed to breathing new life into sectors that are often overlooked, by using state-of-the-art technologies to improve the bioavailability of the active substances of commonly-used medicinal products, and developing delivery systems that are more compatible with the real needs of individuals, in order to improve their Quality of life.
PEARLtec technology is a process for obtaining soft capsules that makes it possible for a liquid matrix to be incorporated into a continuous soft gelatine shell, so improving oral intake of the product and patient compliance.
Orodispersible film (ODF) is a new oral pharmaceutical form, able to improve the treatment compliance of certain groups of subjects whose needs are not met by capsules and tablets.
The prefilled syringes containing the right volume of product, greatly simplifies the administration of sterile solution/substance for injection and reduces the risk of errors, consequently improving safety.
Bag-on-valve (BoV) packaging technology allows to place the product, be it solid or liquid, inside a protective bag, consisting in a laminated, heat-sealed multiply (aluminium and plastic) bag.
The IBSA innovation consists in using this delivery system to guarantee the release of precise doses of medicinal products for oral use dissolved in a pre-set volume.
IBSA has patented exclusive extraction and purification processes and installed equipment dedicated to the production of fertility hormones, gonadotropins, using the urine of pregnant and post-menopausal donors.
IBSA’s research and development has allowed it to place on the market the only progesterone formulation in an aqueous solution, which can be administered subcutaneously.
Single- and multilayer medicated patches are designed to act either locally or systemically. Hydrogel and Drug-in-adhesive technologies are patent-protected.
NAHYCO® HYBRID TECHNOLOGY makes it possible to deliver high doses of hyaluronic acid, thereby improving the viscous and elastic properties of the formulation and improving its resistance to degradation.
The product consists in crystal clear pre-filled syringes and a novel patented medical device that makes it possible to inject a glycosaminoglycan solution into the bladder using a minimally-invasive procedure without requiring catheterisation.
